{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+0.9%25&page=3",
    "query": {
      "intervention": "normal saline 0.9%",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1128,
    "total_pages": 113,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+0.9%25&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+0.9%25&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T13:31:27.641Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02160587",
      "title": "Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "Chloraprep",
          "type": "DRUG"
        },
        {
          "name": "0.9% Physiological Saline",
          "type": "DRUG"
        },
        {
          "name": "ZuraPrep without IPA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Zurex Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2014-07",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02160587"
    },
    {
      "nct_id": "NCT03069911",
      "title": "Trial of OnabotulinumtoxinA for Depression in Parkinson Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease",
        "Depression"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 3,
      "start_date": "2018-11-01",
      "completion_date": "2019-06-01",
      "has_results": false,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03069911"
    },
    {
      "nct_id": "NCT05570448",
      "title": "Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastro Esophageal Reflux"
      ],
      "interventions": [
        {
          "name": "ARAT",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham intervention (control)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Midwest Veterans' Biomedical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-02-15",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570448"
    },
    {
      "nct_id": "NCT03847909",
      "title": "A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 1 (PH1)",
        "Primary Hyperoxaluria Type 2 (PH2)",
        "Kidney Diseases",
        "Urologic Diseases",
        "Genetic Disease"
      ],
      "interventions": [
        {
          "name": "DCR-PHXC",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2019-10-28",
      "completion_date": "2021-06-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-22",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847909"
    },
    {
      "nct_id": "NCT04060316",
      "title": "GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sinusitis Chronic"
      ],
      "interventions": [
        {
          "name": "GLS-1200",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GeneOne Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2023-12",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060316"
    },
    {
      "nct_id": "NCT06375512",
      "title": "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "HZ Vaccine (IN001)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shenzhen Shenxin Biotechnology Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "50 Years to 69 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-07-05",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Hollywood, Florida",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06375512"
    },
    {
      "nct_id": "NCT06253806",
      "title": "Stellate Ganglion Block for COVID-induced Parosmia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19-Induced Parosmia"
      ],
      "interventions": [
        {
          "name": "Stellate Ganglion Block",
          "type": "DRUG"
        },
        {
          "name": "Placebo Sham Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-10-25",
      "completion_date": "2024-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253806"
    },
    {
      "nct_id": "NCT00715364",
      "title": "REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "NTx™-265: rhCG, then rEPO",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stem Cell Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-08",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-05",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Orange, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715364"
    },
    {
      "nct_id": "NCT01336699",
      "title": "Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shigella Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "WRSs2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "WRSs3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 89,
      "start_date": "2013-01-07",
      "completion_date": "2015-05-12",
      "has_results": false,
      "last_update_posted_date": "2019-01-28",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336699"
    },
    {
      "nct_id": "NCT02564016",
      "title": "Efficacy of Labor Epidurals for Postpartum Tubal Ligation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Normal Saline Infusion",
          "type": "DRUG"
        },
        {
          "name": "Capped Epidural",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2014-10",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-06T13:31:27.641Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02564016"
    }
  ]
}